A blood test, which is still in research, has a strong chance of predicting the progression of the disease to those suffering from Multiple Sclerosis. This will result in physicians being able to monitor whether a patient responds to the treatment since the start of the treatment or should a different treatment regimen be chosen to treat and control the disease.
This indicator is added to a set of clinical, laboratory and imaging exams that until now are used successfully by scientists.
The new biomarker, essentially, records the amount of Neuroinducts in the patient’s blood. Substances that are low in the bloodstream of a patient are indicative of a better prognosis of the disease. Otherwise, if Neurofibrils are found at high levels in the blood, this means that the process of demyelination, the damage that is caused by multiple sclerosis, which is manifested in patients with a series of physical and cognitive symptoms, has already begun.
As the scientists highlighted at the European Commission’s annual conference on Therapy and Multiple Sclerosis Study in Berlin, the know-how to manufacture and dispense this test for patients already exists. But much remains to be done, as much research needs to be done to evaluate the credibility of the results of this new promising test before its implementation begins.
As all researchers evolve, this new biomarker, the values of which will be measured in the blood after a simple blood sampling, will significantly change the strategy for treating the disease in the near future, the scientists at the conference argued. Changing the way you administer an important drug for sclerosis further improves its safety.
The interest of doctors involved in the treatment of multiple sclerosis has also pushed the results of a clinical observation on how to administer one of the most well-known drugs to treat multiple sclerosis. Changing the way it was given, significantly improved its safety profile.
They saw that intravenous administration of the drug to patients, at shorter intervals and in particular over 4 weeks, greatly reduced the already low risk of these patients experiencing a serious form of encephalopathy. This is the progressive multifocal leukoencephalopathy, which is triggered by the virus that is found in more than hateful people but remains inactive in the kidneys.
The drug Natalizumab, marketed in our country since 2007 with an indication for use in patients with high disease activity and one of the most important drugs for Recurrent Intermittent Multiple Sclerosis, rarely (about 4 per thousand) was responsible for activation of this virus and the challenge of encephalopathy.
With sparse administration of the drug, the risk of developing this serious side effect seems to be further diminished, researchers said, presenting the latest data. Of course, it is worth noting that to date the treatment is completely personalized. For patient-positive patients who are likely to develop this encephalopathy as a side effect, there is a risk minimization plan aimed at patient safety.
As far as its effectiveness is concerned, newer data regarding the observation of the last 10 years and announced at the conference confirm its action especially in early onset patients. MRI remains the most reliable diagnostic tool for patients with Multiple Sclerosis.
Magnetic resonance imaging is, as is well known, an examination that basically records the imaging activity of the disease, those suffering from multiple sclerosis. For this reason, the accuracy of the results of this test is important, stressed the scientists, explaining that there are often variations in the patient’s magnetic resonance imaging, depending on the technology used.
Their recommendation is to use the same diagnostic protocol in magnetic tomography to avoid any discrepancies in the findings, which even confuse the doctors themselves. As once again, the value of MRI is invaluable in patients with multiple sclerosis as it can prevent (if present) the progression of the disease without necessarily occurring symptoms.